Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof

Patent metadata

Field	Value
Publication number	US-9650387-B2
Application number	US-201615076586-A
Country	US
Kind code	B2
Filing date	Mar 21, 2016
Priority date	Jul 2, 2009
Publication date	May 16, 2017
Grant date	May 16, 2017

Abstract

The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

First claim

We claim:

1. A composition comprising 13.34 mg benzoate-hydrocodone hydrochloride conjugate, wherein the conjugate has the following structure:

wherein the conjugate is provided in a gel formulation.

2. The composition of claim 1 , wherein the 13.34 mg benzoate-hydrocodone hydrochloride contains a molar equivalent of 9.08 mg of hydrocodone.

3. The composition of claim 1 , wherein the gel formulation further comprises a soft gel.

4. The composition of claim 1 further comprising 650 mg acetaminophen.

5. A composition comprising 26.68 mg benzoate-hydrocodone hydrochloride conjugate, wherein the conjugate has the following structure:

wherein the conjugate is further provided in a gel formulation.

6. The composition of claim 5 further comprising 1300 mg acetaminophen.

7. The composition of claim 6 , wherein the conjugate results in the mean C max of hydrocodone of about 75,100 pg/mL±25,500 pg/mL when administered orally to a human.

8. The composition of claim 6 , wherein the conjugate results in the mean T max of hydrocodone of about 1.17 hours when administered orally to a human.

9. The composition of claim 6 , wherein the conjugate results in the range of T max of hydrocodone from about 0.6 hours to about 4.12 hours when administered orally to a human.

10. The composition of claim 6 , wherein the conjugate results in the mean AUC 0-0.5h of hydrocodone of about 12,530 h×pg/mL±7,213 h×pg/mL when administered orally to a human.

11. The composition of claim 6 , wherein the conjugate results in the mean AUC 0-1h of hydrocodone of about 42,520 h×pg/mL±20,200 h×pg/mL when administered orally to a human.

12. The composition of claim 6 , wherein the conjugate results in the mean AUC 0-2h of hydrocodone of about 95,850 h×pg/mL±29,510 h×pg/mL when administered orally to a human.

13. The composition of claim 6 , wherein the conjugate results in the mean AUC 0-4h of hydrocodone of about 172,200 h×pg/mL±39,550 h×pg/mL when administered orally to a human.

14. The composition of claim 6 , wherein the conjugate results in the mean AUC 0-8h of hydrocodone of about 269,000 h×pg/mL±51,840 h×pg/mL when administered orally to a human.

15. The composition of claim 6 , wherein the conjugate results in the mean AUC 0-24h of hydrocodone of about 382,100 h×pg/mL±81,260 h×pg/mL when administered orally to a human.

16. The composition of claim 6 , wherein the conjugate results in the mean AUC inf of hydrocodone of about 392,800 h×pg/mL±86,300 h×pg/mL when administered orally to a human.

17. The composition of claim 6 , wherein the conjugate results in the mean t 1/2 of hydrocodone of about 4.99 hours±0.79 hours when administered orally to a human.

18. A composition comprising 53.36 mg benzoate-hydrocodone hydrochloride conjugate, wherein the conjugate has the following structure:

wherein the conjugate is provided in a gel formulation.

19. The composition of claim 18 further comprising 2600 mg acetaminophen.

20. The composition of claim 19 , wherein the conjugate results in the mean C max of hydrocodone of about 147,000 pg/mL±54,100 pg/mL when administered orally to a human.

21. The composition of claim 19 , wherein the conjugate results in the mean T max of hydrocodone of about 1.05 hours when administered orally to a human.

22. The composition of claim 19 , wherein the conjugate results in the range of T max of hydrocodone from about 0.6 hours to about 4.12 hours when administered orally to a human.

23. The composition of claim 19 , wherein the conjugate results in the mean AUC 0-0.5h of hydrocodone of about 26,900 h×pg/mL±14,770 h×pg/mL when administered orally to a human.

24. The composition of claim 19 , wherein the conjugate results in the mean AUC 0-1h of hydrocodone of about 88,750 h×pg/mL±42,380 h×pg/mL when administered orally to a human.

25. The composition of claim 19 , wherein the conjugate results in the mean AUC 0-21 , of hydrocodone of about 193,400 h×pg/mL±66,470 h×pg/mL when administered orally to a human.

26. The composition of claim 19 , wherein the conjugate results in the mean AUC 0-4h of hydrocodone of about 353,500 h×pg/mL±97,670 h×pg/mL when administered orally to a human.

27. The composition of claim 19 , wherein the conjugate results in the mean AUC 0-8h of hydrocodone of about 566,900 h×pg/mL±128,200 h×pg/mL when administered orally to a human.

28. The composition of claim 19 , wherein the conjugate results in the mean AUC 0-4h of hydrocodone of about 811,900 h×pg/mL±175,100 h×pg/mL when administered orally to a human.

29. The composition of claim 19 , wherein the conjugate results in the mean AUC inf of hydrocodone of about 842,100 h×pg/mL±190,800 h×pg/mL when administered orally to a human.

30. The composition of claim 19 , wherein the conjugate results in the mean t 1/2 of hydrocodone of about 4.92 hours±0.95 hours when administered orally to a human.

31. A composition comprising 80.04 mg benzoate-hydrocodone conjugate, wherein the conjugate has the following structure:

wherein the conjugate is provided in a gel formulation.

32. The composition of claim 31 further comprising 3900 mg acetaminophen.

33. The composition of claim 31 , wherein the conjugate results in the mean C max of hydrocodone of about 208,000 pg/mL±87,300 pg/mL when administered orally to a human.

34. The composition of claim 31 , wherein the conjugate results in the mean T max of hydrocodone of about 1.05 hours when administered orally to a human.

35. The composition of claim 31 , wherein the conjugate results in the range of T max of hydrocodone from about 0.6 hours to about 4.15 hours when administered orally to a human.

36. The composition of claim 31 , wherein the conjugate results in the mean AUC 0-0.5h of hydrocodone of about 37,140 h×pg/mL±22,750 h×pg/mL when administered orally to a human.

37. The composition of claim 31 , wherein the conjugate results in the mean AUC 0-1h of hydrocodone of about 121,900 h×pg/mL±65,280 h×pg/mL when administered orally to a human.

38. The composition of claim 31 , wherein the conjugate results in the mean AUC 0-2h of hydrocodone of about 263,500 h×pg/mL±103,300 h×pg/mL when administered orally to a human.

39. The composition of claim 31 , wherein the conjugate results in the mean AUC 0-4h of hydrocodone of about 487,500 h×pg/mL±154,300 h×pg/mL when administered orally to a human.

40. The composition of claim 31 , wherein the conjugate results in the mean AUC 0-8h of hydrocodone of about 816,300 h×pg/mL±208,800 h×pg/mL when administered orally to a human.

41. The composition of claim 31 , wherein the conjugate results in the mean AUC 0-24h of hydrocodone of about 1, 217, 00 h×pg/mL±296,800 h×pg/mL when administered orally to a h

Assignees

• Kempharm Inc

Inventors

• Mickle Travis
• Guenther Sven
• Mickle Christal
• Chi Guochen
• Kanski Jaroslaw
• Martin Andrea K
• Bera Bindu

Classifications

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K31/167 Primary

  having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title